Preliminary full year 2021 total revenues were $579.8 million; an 11% increase compared to $520.4 million in 2020
SPN-830 (apomorphine infusion device) NDA accepted for review by FDA; PDUFA date early October 2022
Completed acquisition of Adamas Pharmaceuticals, Inc. in November 2021; integration well underway
Qelbree® continued its growth trajectory, closing the year with 13,380 prescriptions in December 2021
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.